Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16931439 | 0.88 | MAPT (0.52) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL30021896 | 0.86 | MAPT (0.57) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL23612029 | 0.86 | MAPT (0.57) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL3174381 | 0.86 | MAPT (0.57) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL29546457 | 0.85 | MAP4K4 (0.59) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL110185 | 0.85 | MAP4K4 (0.59) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL31257432 | 0.83 | MAPT (0.54) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL29318821 | 0.83 | MAPT (0.54) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL25353652 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTLMNAMAP4K4CKS1B | |
| SCHEMBL2142014 | 0.82 | MAP4K4 (0.55) | ALDH1A1MAPTLMNAMAP4K4CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | claimed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | claimed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | claimed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112754-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-2438063-A1 | 1H-IMIDAZO[4,5-C]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139747-A1 | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311714-A1 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS | PRKCA, ABL1, MYLK2 | ALDH1A1 2472/4885MAPT 1605/4885LMNA 811/4885 |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | NTRK2, MUSK, NTRK3 | ALDH1A1 2033/4885MAPT 3492/4885LMNA 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.